Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
Bagsværd, Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational…
ModelOp Recognized in 2025 Gartner® Market Guide for AI Governance Platforms
Market Value Lower Than Cash Assets? It’s Time to Reevaluate NIVF
Winvest Group Announces Strategic Partnership with Greater Bay Area RWA Incubator; Southeast Asia Headquarters to Be Established in Malaysia